… The Japanese authorities arrested seven central figures in the huge accounting scandal at Olympus — including the camera maker’s former chairman and executive vice president — on Thursday as part of investigations into a decade-long cover-up that has prompted … Continue reading →
Categories: Ideas For Surgery News |
Tags: $2 billion acquisition , 2012 California Biomedical Industry Report , Academic and regional medical facilities , Accelerate Globalization , Accelerated investments , accelerated investments to serve the emerging markets , accelerating globalization , Access to capital , acquisition of technologies , acroMIS Consulting , acromis implementation and development , address patients’ need , address the high risk , adoption of austerity measures , advantageous position , adverse impact on technology , age-related disease , Akio Nakagawa , Altis , Altis and Humalabo , angel investors , around the globe , Asia , Attain the desired level of proficiency , availability of capital to fund future innovation , AXAM , AXAM Investments Inc. , Axes , Axes America LLC , Axes America’s President and CEO , Axes Investment Management Co. , Axes Securities , Axes Securities Co , bankrupt , BayBio , biggest long-term opportunity , Biomedical Access to Capital , biomedical cluster , biomedical company CEOs , Biomedical industry , biomedical innovation , biotechnology , British medical company Gyrus , burdensome and uncertain regulatory environment , business in financial transactions , California’s biomedical industry , Candidates in queue , Cayman Islands , CE Mark trial , CE Mark trial of the next-generation , CEO , CEO of ITX , challenging environment , CHI-California Healthcare Institute , choosing the right delivery method , clinical value , Collaboration and capitation strategies , Collaborative partnership , commercialize medtech , Compete on price , Competitive landscape , competitive landscape is likely to change , Congress , considered as a first line therapy , constrained healthcare budgets , corporate finance , corporate partnerships as a source of financing , corporate venture capital as a finance source , Corporate venture funding , Cost reduction and value creation , Cost vs Value , cost-effective solutions , Coverage and reimbursement issues , coverage and reimbursement issues are extremely important , critical decision factor , current global economic situation , cyclical problem of depressed macroeconomic conditions , dealing with high risk complications , declining procedure volume , delay a research or development project , Deliver value , deliver value to the overall healthcare system , delivered through two approaches , delivering better economic value , Demonstrate the economic value , demonstrate the economic value at both the provider and payer levels , Develop specific plans to accelerate global growth , develop specific plans to accelerate our global growth , devices approved for procedures , devices are priced at a hefty premium , Devices priced at hefty premium , diagnostics or medical equipment , Disease foundations , disease foundations/non-governmental organizations , dispute , Disruptive business model , disruptive business models , Diverse funding sources , dormant , Drexel , Drexel Burnham Lambert , Dynamic Dragons , each of the major emerging markets , economic downturn , Economic potential , economic potential of this specialized , emerging markets , engaging primarily with the physician , Enrollment in pilot study , enrollment in the pilot study , evaluated the merits of our products solely on the clinical value , Evaluated the merits of products , Evolving Market , Expanding insights into markets , expanding insights into these markets , FDA has the best regulatory approval process in the world , FDA regulatory approval process , Findings of the CEO Survey , FINRA records , first mover advantage , focus on emerging markets , force the players to increasingly compete on price , forced to look for other solutions , Forty-four percent of biomedical CEOs surveyed said they will look to licensing agreements , G.C. Venture Capital , Germany , Global Chef , Global Company , Global Company’s CEO Yokoo Nobumasa had also been CEO of Humalabo’s predecessor company L.E.M. Hanbai , global growth goals , global leadership position , Global Markets , global P&L responsibility , government grants , Growth opportunity , growth opportunity for our industry , Gyrus deal , Haio Fauser is a local market expert in each of the geographic regions , Hajime “Jim” Sagawa , Hajime Sagawa , Hamada Masayuki , Hayashi Masayuki , hide losses , high surgical risk , Hirata Kiichi , Humalabo , Ichimura Takuya , Implantable medical devices IMD , Implementation , Improve Execution , Improving ability to attract investment and grow , improving our ability to attract investment and grow , in the OUS market , increased pressure in utilization , independent investigation from the company’s top institutional shareholders , informal capacity , Innovation , innovation and state-of-the-art medical technology , innovative technologies , IntelliSense Fine Force Technology , Intraluminal , investigations from government , Investment firm , Investment Management , Investment of corporate funds into external endeavors , issues being discussed throughout the biomedical industry by executives , J Alternative , J Bridge/Asia Alliance Holdings , Japan , Japanese camera maker Olympus , Japanese market , job creation , Joint Ventures , Kawada Hitoshi , Key Opinion Leader Connections , key opinion leader KOL , Kobe University in Economics , KOL Physicians , Kosaka Kiyoshi , Lack of funding , lack of innovation and productivity , laparoscopic vascular and endovascular capabilities , laparoscopic vascular and endovascular treatments , leadership position , Leading biomedical region , less invasive treatment , licensing agreements , Look for other solutions , lower extremity arterial disease , Ltd. , M&A deal , Maintain high standards of safety and effectiveness , maintain the high standards of safety and effectiveness , Major emerging markets , maker of microwavable plastic , many patients with age working against them , market in Europe , Marketing , Masayuki Hamada , massive decline in Olympus stock price , Matsumoto Kuniaki , Medical , Medical device , medical device industry , medical device innovation , Medical devices , medical devices companies , Medical technology , MedTech , meet the urgent need of patients , Meeting the needs , meeting the needs of the billions of people in emerging markets , Mergers & Acquisitions , Merrill Lynch , Michael Woodford , Minimal comparative clinical evidence , modality for abdominal aortic aneurysm repair , Mori Hisashi , multinational , Murata Masami , myriad of complications , mysterious payment , Nakagawa Akio , nascent technologies , necessity of the procedures to be performed in specialized centers , Neo Strategic Venture LP , Neuro/ spine , New Investments Ltd. , new medical devices , News Chef , Next-generation , NIOBE magnets , Nishihata Youhei , Nishimori Hitoshi , Nissho Iwai , Nobel Prize winning economist , Nomura , Nomura Securities , Non-governmental organizations NGO , noninvasive , obscure , Olympus Executive Vice President , onditions , Operating room , Operational assessment , Optimize Innovation , Optimize Innovation And Accelerate Globalization , OR efficiencies solutions , OUS market , outside the US OUS , Outside The USA (OUS) , Outside The USA (OUS) Global Markets Amid Soft US Sales , overt risk , Paine Webber , PaineWebber , paradigm-changing , partnerships , Percutaneous or surgical , Performance vs Targets , Perioperative health care technologies , pharmaceuticals , Physician Preference Items PPI , physicians may have to perform 30 cases before they attain the desired level of proficiency , physicians’ learning curve , pivotal trial , Portfolio Management , preclinical evidence , preclinical studies , prevailing economic uncertainty , PricewaterhouseCoopers (PwC) , principle investigator , Prioritize investment , Product Development , products in clinical development , progressive , project delays cited by private company CEOs , Proof-of-concept Lab Trials , proper selection of patients , prospective studies , Provider and payer levels , providing expertise. early clinical evidence , proximal aortic anastomosis , PwC , R&D , Raising money for a startup , recent launches , Recreate the ecosystem , recreate the ecosystem that has made the US the leading biomedical region , regulatory and reimbursement processes , Regulatory approval process in the world , regulatory changes , Regulatory Environment will Determine R&D Productivity , Regulatory framework based on consistency , regulatory framework that is based on consistency , reimbursement pressure , remote device manipulation system , remotely direct the catheter tip , renal aortic pathologies , representatives on their staff from each region , resources , restructuring initiatives , review our businesses , Robert Mundell , Robot-assisted intervention , Robot-assisted laparoscopic aortic procedures , robot-assisted laparoscopic aortic surgery , robotic computer-enhanced telemanipulation systems , robotic surgery , robotic technology , Robotically steerable endovascular catheter systems , robotics , Sagawa & Company , Sagawa Capital , Sagawa International Services , Sanyo Securities America , Sato Hideki , scheduled for completion , seeking diverse funding sources , serial entrepreneur , Services to hospital leaders , shareholders , slower growth of US markets , snapshot of the biomedical industry in California , Sojitz , solutions that deliver better economic value , source of funding to the industry , special-purpose investment vehicles , splenic and renal artery aneurysm reconstruction , Stakeholders , Standard of care , state-of-the-art procedure , steerable catheter , Sterotaxis , Strategic Planning , Strategy Development , strong and collaborative partnership between our business , surgical robotics , Surgical supplies cost reduction , sustainable growth , System and process focused , Tactical Execution of Commercialization Programs , Takahashi Yoshinori , Tanabe Souhei/Shouhei , targeting a limited launch , tax incentives for innovation , Team work , Techno Mining Ltd. , Technological innovations , The CEO Survey , the current FDA regulatory approval process has slowed the growth , the current trajectory of rising healthcare costs is unsustainable , the future of global economic recovery , the investment of corporate funds into external endeavors , the standard of care , threats to the biomedical industry’s growth , To Improve Execution , top executive , Training of the physicians and staff , training of the physicians and staff is significant , two mysterious sets of corporate deals , UBS AG , Uncertain regulatory environment , Under development , unfavorable reimbursement decision from the CMS , Unsuitable for open surgery , unsuitable for this open surgery , Value-based health care , Wasserstein Perella & Co. , we must prioritize our investment , widespread economic uncertainty , Widespread rollout , Working collaboratively , Working collaboratively with other stakeholders , www.axesim.co.jp , Yokoo Akinobu , Yokoo Nobumasa , Yoshida Minoru , Yoshikai Ryuzo |
Permalink
